Advances in Escherichia coli Nissle 1917 as a customizable drug delivery system for disease treatment and diagnosis strategies
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
With the in-depth and comprehensive study of bacteria and their related ecosystems in the human body, bacterial-based drug delivery system has become an emerging biomimetic platform that can retain the innate biological functions. Benefiting from its good biocompatibility and ideal targeting ability as a biological carrier, Escherichia coli Nissle 1917 (ECN) has been focused on the treatment strategies of inflammatory bowel disease and tumor. The advantage of a bacterial carrier is that it can express exogenous protein while also acting as a natural capsule by releasing drug slowly as a result of its own colonization impact. In order to survive in harsh environments such as the digestive tract and tumor microenvironment, ECN can be modified or genetically engineered to enhance its function and host adaptability. The adoption of ECN carries or expresses drugs which are essential for accurate diagnosis and treatment. This review briefly describes the properties of ECN, the relationship between ECN and inflammation and tumor, and the strategy of using surface modification and genetic engineering to modify ECN as a delivery carrier for disease treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isabella, V. M., Ha, B. N., Castillo, M. J., Lubkowicz, D. J., Rowe, S. E., Millet, Y. A., Anderson, C. L., Li, N., Fisher, A. B., West, K. A., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4222 · Cited by 605
Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity
Ukena, S. N., Singh, A., Dringenberg, U., Engelhardt, R., Seidler, U., Hansen, W., Bleich, A., Bruder, D., Franzke, A., Rogler, G., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001308 · Cited by 482
Kurtz, C. B., Millet, Y. A., Puurunen, M. K., Perreault, M., Charbonneau, M. R., Isabella, V. M., Kotula, J. W., Antipov, E., Dagon, Y., Denney, W. S., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau7975 · Cited by 399
Sonnenborn, U. (2016) · FEMS Microbiology Letters · doi:10.1093/femsle/fnw212 · Cited by 315 · cited 1×
“Moreover, the two plasmids have been sequenced and proved to be genetically stable and untransferable, which provides materials for subsequent gene editing of ECN plasmids [70,71].”
BackgroundMaltby, R., Leatham-Jensen, M. P., Gibson, T., Cohen, P. S., & Conway, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053957 · Cited by 285 · cited 1×
“ECN can also inhibit the colonization of pathogenic bacteria (such as enterohemorrhagic Escherichia coli) and the production of toxins (such as Shiga toxinproducing Escherichia coli), thereby maintaining the stability of the intestinal flora [31, 32].”
BackgroundBär, F., Von Koschitzky, H., Roblick, U., Bruch, H. P., Schulze, L., Sonnenborn, U., Böttner, M., & Wedel, T. (2009) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2008.01258.x · Cited by 113
Expressing cytotoxic compounds in Escherichia coli Nissle 1917 for tumor-targeting therapy
Li, R., Helbig, L., Fu, J., Bian, X., Herrmann, J., Baumann, M., Stewart, A. F., Müller, R., Li, A., Zips, D., et al. (2019) · Research in Microbiology · doi:10.1016/j.resmic.2018.11.001 · Cited by 73
Guo, S., Chen, S., Ma, J., Ma, Y., Zhu, J., Ma, Y., Liu, Y., Wang, P., & Pan, Y. (2019) · Mediators of Inflammation · doi:10.1155/2019/5796491 · Cited by 64
Self-citation
Cited by
Zhu, L., Song, G., Zhang, W., Wu, Y., Chen, Y., Song, J., Wang, D., Li, G., Tang, B. Z., & Li, Y. (2025) · Nature Communications · doi:10.1038/s41467-025-57533-y · Cited by 63
Yang, S., Sheffer, M., Kaplan, I. E., Wang, Z., Tarannum, M., Dinh, K., Abdulhamid, Y., Bobilev, E., Shapiro, R., Porter, R., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-024-02418-6 · Cited by 66
Next‐Generation Probiotics: From Traditional Strains to Personalized Therapeutics
Jadhav, N. K., Magdum, A. B., Shinde, K. V., & Nimbalkar, M. S. (2026) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.70339 · Cited by 29
“The nano-coating protects the bacteria from the gastric environment, allowing more viable cells to reach the intestines and restore gut flora [84].”
Bile resistance mechanisms in probiotics: From structural adaptation to metabolic regulation
Hu, J.-W., Guo, S.-J., Zhang, L.-W., & Guo, C.-F. (2026) · Food Bioscience · doi:10.1016/j.fbio.2026.108282 · Cited by 5
Wang, K., & Yan, C. (2026) · Archives of Microbiology · doi:10.1007/s00203-026-04907-5 · Cited by 1
Metadata
- Authors
- Chen, H., Lei, P., Ji, H., Yang, Q., Peng, B., Ma, J., Fang, Y., Qu, L., Li, H., Wu, W., Jin, L., & Sun, D.
- Venue
- Materials Today Bio
- Publisher
- Elsevier BV
- Published
- 2023-02
- Volume
- 18
- Pages
- 100543
- ISSN
- 2590-0064 (ISSN-L)
- OpenAlex
- W4313551959
- Cited by
- 120
- References
- 8
- FWCI
- 13.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances in Escherichia coli Nissle 1917 as a customizable drug delivery system for disease treatment and diagnosis strategies. https://app.cochat.ai/papers/10.1016/j.mtbio.2023.100543
- The paper
- Chen, H., Lei, P., Ji, H., Yang, Q., Peng, B., Ma, J., Fang, Y., Qu, L., Li, H., Wu, W., Jin, L., & Sun, D. (2023). Advances in Escherichia coli Nissle 1917 as a customizable drug delivery system for disease treatment and diagnosis strategies. Materials Today Bio. https://doi.org/10.1016/j.mtbio.2023.100543
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.